An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
CareDx, a precision medicine company, granted an option to purchase 700,706 shares of common stock and 487,804 restricted stock units to its new President and CEO, John Hanna. The option has an exercise price of $8.20 and will vest over four years, while the RSUs will vest in four equal, annual installments beginning on April 15, 2025. This grant was approved by the board of directors as an inducement material to Mr. Hanna's employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
CareDx, società specializzata in medicina di precisione, ha concesso a John Hanna, il nuovo Presidente e CEO, un'opzione per acquistare 700.706 azioni ordinarie e 487.804 unità di stock riservate. L'opzione ha un prezzo di esercizio di 8,20 dollari e maturerà nell'arco di quattro anni, mentre le unità di stock riservate matureranno in quattro rate annuali uguali a partire dal 15 aprile 2025. Questa concessione è stata approvata dal consiglio di amministrazione come incentivo significativo per l'assunzione del signor Hanna, in conformità con la regola di quotazione Nasdaq 5635(c)(4).
CareDx, una empresa de medicina de precisión, concedió una opción para comprar 700.706 acciones comunes y 487.804 unidades de acciones restringidas a su nuevo Presidente y CEO, John Hanna. La opción tiene un precio de ejercicio de $8.20 y se otorgará en cuatro años, mientras que las unidades de acciones restringidas se otorgarán en cuatro entregas anuales iguales comenzando el 15 de abril de 2025. Esta concesión fue aprobada por el consejo directivo como un incentivo material para el empleo de Mr. Hanna, de acuerdo con la Regla de Listado de Nasdaq 5635(c)(4).
정밀 의학 회사인 CareDx는 새 회장이자 CEO인 존 하나에게 700,706주의 보통주와 487,804주의 제한 주식 단위를 구매할 수 있는 옵션을 부여했습니다. 이 옵션의 실행 가격은 $8.20이며 4년에 걸쳐 조건이 충족될 것입니다. 제한 주식 단위는 2025년 4월 15일부터 시작하여 매년 같은 비율로 4년 동안 부여됩니다. 이 임명은 나스닥 상장 규칙 5635(c)(4)에 따라 하나 씨의 고용을 위한 중요한 유인으로 이사회에서 승인되었습니다.
CareDx, une entreprise de médecine de précision, a accordé une option d'achat de 700 706 actions ordinaires et 487 804 unités d'actions restreintes à son nouveau président et directeur général, John Hanna. L'option a un prix d'exercice de 8,20 $ et sera acquise sur quatre ans, tandis que les unités d'actions restreintes seront acquises en quatre versements annuels égaux à partir du 15 avril 2025. Cette attribution a été approuvée par le conseil d'administration comme une incitation matérielle à l'emploi de M. Hanna, conformément à la Règle de cotation Nasdaq 5635(c)(4).
CareDx, ein Unternehmen für Präzisionsmedizin, gewährte John Hanna, dem neuen Präsidenten und CEO, eine Option zum Kauf von 700.706 Stammaktien und 487.804 eingeschränkten Aktieneinheiten. Die Option hat einen Ausübungspreis von 8,20 Dollar und wird über vier Jahre vestieren, während die RSUs in vier gleichen jährlichen Raten ab dem 15. April 2025 vestieren werden. Diese Zuteilung wurde vom Vorstand als wesentlicher Anreiz für die Anstellung von Herrn Hanna genehmigt, gemäß der Nasdaq Listing Rule 5635(c)(4).
Positive
None.
Negative
None.
BRISBANE, Calif.--(BUSINESS WIRE)--
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on April 15, 2024, CareDx granted an option to purchase 700,706 shares of CareDx’s common stock (the “Inducement Option”) and 487,804 restricted stock units (the “Inducement RSUs” ) to John Hanna, CareDx’s newly appointed President and Chief Executive Officer. The Inducement Option and the Inducement RSUs were approved by the Compensation and Human Capital Committee of CareDx’s board of directors on March 25, 2024, and were an inducement material to Mr. Hanna’s employment with CareDx in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Option has an exercise price of $8.20 and will vest over four years, with 25% of the total number of shares subject to the Inducement Option vesting on April 15, 2025, the one-year anniversary of the date of commencement of Hanna’s employment with CareDx, and 1/48th of the total number of shares subject to the Inducement Option vesting at the end of each calendar month thereafter, subject in each case to Hanna’s continued services with CareDx on each vesting date. The Inducement RSUs will vest in four equal, annual installments beginning on April 15, 2025, the one-year anniversary of the date of commencement of Hanna’s employment with CareDx, subject in each case to Hanna’s continued services with CareDx on each vesting date.
CareDx is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.
Forward-Looking Statements
This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the equity grants. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed by CareDx with the SEC on February 28, 2024, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
How many shares of common stock were granted to John Hanna?
John Hanna was granted an option to purchase 700,706 shares of CareDx's common stock.
What is the exercise price of the Inducement Option?
The exercise price of the Inducement Option is $8.20.
When will the Inducement RSUs vest?
The Inducement RSUs will vest in four equal, annual installments beginning on April 15, 2025.
Why were the Inducement Option and RSUs granted to John Hanna?
The Inducement Option and RSUs were granted to John Hanna as an inducement material to his employment with CareDx, in accordance with Nasdaq Listing Rule 5635(c)(4).
caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos
